Nurix Therapeutics

IPO

Nurix | Medicines to Outmatch Disease

Public · San Francisco, United States · Founded 2009 · $162.0M raised

Employees
51–200
Founded
2009
Business Model
B2B
Total Funding
$162.0M
Last Round
$102.0M Series CJan 2019
Rounds
2
Type
Public

About

At Nurix Therapeutics, we aim to fundamentally change the way disease is treated using degrader-based medicines. Founded on groundbreaking research from UC Berkeley and UC San Francisco, Nurix started as an E3 ligase-centric company whose DEL-AI discovery engine integrates DNA-encoded libraries, ligase binders, automated chemistry, and machine learning. That platform lets Nurix develop targeted protein degradation therapies in parallel against a broad set of targets for patients who need options beyond current treatments.

Summary

Nurix Therapeutics is a Biotech company based in San Francisco, United States, founded in 2009. It has raised $162.0M in total across 2 rounds, most recently a $102.0M Series C round in Jan 2019. Investors include Deerfield Management.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOAug 2020
$176.0M

Sign up to see all 3 rounds

Series B through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Nurix Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/nurix-therapeutics"><img src="https://indexed.vc/api/badge/company/nurix-therapeutics" alt="Nurix Therapeutics on Indexed.vc" width="260" height="76" /></a>